This site is intended for healthcare providers. If you’re a patient, please click here.
Proven efficacy and satisfaction.
'/%3e%3c/svg%3e)
0%
achieved wrinkle severity of none or mild at week 4 per investigator's assessment.2*
0%
of patients were satisfied with their treatment at week 4.2*
*Per pooled data from SAKURA 1 and SAKURA 2.2,4 74% achieved a ≥ 2-grade
improvement at week 4 per both physician’s and patient’s
assessment.2,4
Smooths out frown lines fast.1,3
Most users see results as early as the next day and typically within two days after treatment.4*
*Based on pooled patient diary data from SAKURA 1 and SAKURA 2.1,2,4
Patient results after 2 days. Results may vary.
Before
2 days after
Long-lasting results. Gradual softening.2
DAXXIFY® offers sustained glabellar line improvement* and gradually softens over a prolonged period.2†
*More than 50% of patients in SAKURA 1 and SAKURA 2 had no or mild frown lines for
24 weeks (6 months) and 23.9 weeks (6 months) or longer, respectively, per both
physician’s and patient’s assessments.10
†Median time to return to baseline wrinkle severity was
27.7 weeks in SAKURA 1 and 26 weeks in SAKURA 2.10
SAKURA 14a
SAKURA 24b
aPivotal, placebo-controlled, single-treatment trial
conducted at 15 sites over 36 weeks; N=303 (DAXXIFY®: 201; placebo:
102).4
bPivotal, placebo-controlled, single-treatment trial
conducted at 15 sites over 36 weeks; N=306 (DAXXIFY®: 205; placebo:
101).4
cProportion of patients from SAKURA 1 and SAKURA 2
rated as 0 or 1 (none or mild) by the investigator.4
dProportion of patients from SAKURA 1 and SAKURA 2
rated as 0 or 1 by the patient.4
74% achieved a ≥2−grade improvement at week 4 per both investigator’s and patient’s assessments.2,4§
§Per pooled data from SAKURA 1 and SAKURA 2.2,4
Radiant-looking results3
of patients rated their skin's appearance as radiant/bright after treatment.3*
*In an open label study (N=27), 89% of patients agreed their skin looked radiant/bright (exploratory endpoint).3
Patient safety.
In the largest clinical study of its kind, DAXXIFY® proved to be highly effective without compromising safety.2,10,17,18 Clinical trials demonstrate that DAXXIFY® is generally safe and well tolerated, with no serious treatment-related adverse events reported.2,4
ADVERSE REACTIONS ≥1% AND MORE FREQUENT THAN PLACEBO IN
SAKURA 1 AND SAKURA 2 (POOLED)4 | DAXXIFY® n=406 n (%) | PLACEBO n=203 n (%) |
| HEADACHE | 26 (6%) | 4 (2%) |
| EYELID PTOSIS | 9 (2%) | 0 (0%) |
FACIAL PARESISa | 5 (1%) | 0 (0%) |
aFacial paresis, including facial asymmetry, is a broad term in the adverse event coding system, and in SAKURA 1 and SAKURA 2 this included 1 patient with unilateral over-arched brow and 4 patients with frontalis muscle weakness.4,19
The incidence of these adverse reactions did not increase with multiple retreatments.4
The most common side effects seen in clinical trials occurred within one to two weeks after injection and lasted only a short while. This is consistent with other neuromodulator treatments.20
In the repeat-dose, open-label SAKURA 3 safety study, 2,691 patients were treated with 40U of DAXXIFY®. The adverse reaction profile was similar to that reported in single-dose trials.4,18 Injection site reactions were the most common adverse reactions, reported in 9% of patients [including injection site pain (4%), injection site erythema (3%), injection site edema (3%), injection site bruising (1%), injection site papule (<1%), and injection site pruritus (<1%)], followed by headache (5%), edema (2%), erythema (2%), and eyelid ptosis in 1% of patients.4
Proven efficacy.
Read up on the peer-reviewed evidence of DaxibotulinumtoxinA and its effectiveness in treating frown lines.
Journal of the American Academy of Dermatology
Plastic and Reconstructive Surgery
Toxins journal
Ready to show your patients the DAXXIFY® Difference?
Contact us today to start offering DAXXIFY® at your practice.